



**New Hampshire Medicaid Fee-for-Service (FFS) Program
Prior Authorization/Non-Preferred Drug Approval Form
Long-Acting Opioid Analgesic**

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY (Continued)

8. Do you attest that the NH Prescription Drug Monitoring Program has been reviewed in the last 60 Yes No days?

9. Does the patient have a written pain agreement? Yes No

10. Has the patient tried and failed or is patient not a candidate for at least 3 of the following? Yes No

Provide details below:

- a. Topical NSAIDS: _____
- b. Oral NSAIDS: _____
- c. Oral Acetaminophen: _____
- d. Transcutaneous electrical nerve stimulation: _____

11. Will the patient be prescribed concurrent naloxone? Yes No

Provide any additional information that would help in the decision-making process. *If additional space is needed, please use a separate sheet.*

SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERIA

Chapter 188 of the Laws of 2004 requires that Medicaid only cover non-preferred drugs upon a finding of medical necessity by the prescribing physician. Chapter 188 requires that you base your determination of medical necessity on the following criteria.

Allergic reaction. Describe reaction:

Drug-to-drug interaction. **Describe reaction:**

Previous episode of an unacceptable side effect or therapeutic failure. **Provide clinical information:**

(Form continued on next page.)



**New Hampshire Medicaid Fee-for-Service (FFS) Program
Prior Authorization/Non-Preferred Drug Approval Form
Long-Acting Opioid Analgesic**

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERIA (Continued)

Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to a preferred drug.

Provide clinical information:

Age-specific indications. **Provide patient age and explain:**

Unique clinical indication supported by FDA approval or peer-reviewed literature. **Explain and provide a reference:**

Unacceptable clinical risk associated with therapeutic change. **Please explain:**

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE:** _____